Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-05-16

FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) by AbbVie. This action approves changes to its labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kaletra (lopinavir)

Snippet

SUPPL AP for KALETRA (LOPINAVIR AND RITONAVIR)